{"id":8387,"date":"2025-02-04T09:37:44","date_gmt":"2025-02-03T22:37:44","guid":{"rendered":"https:\/\/www.optalert.com\/?p=8387"},"modified":"2026-09-16T14:54:35","modified_gmt":"2026-09-16T04:54:35","slug":"app-owl-eye-detecta-signos-de-problemas-de-sueno-en-minutos","status":"publish","type":"post","link":"https:\/\/www.optalert.com\/es\/owl-eye-app-detects-signs-of-sleep-issues-in-minutes\/","title":{"rendered":"La app Owl Eye detecta signos de problemas de sue\u00f1o en minutos"},"content":{"rendered":"

Our team at Optalert has been dedicated to innovation in sleep science for two decades now. Today, we are proud to announce that our pioneering sleep science research team has developed a unique biomarker for rapidly detecting signs of sleep issues with astonishing accuracy. The Owl Eye test is free, easy to use, takes minutes to complete, and only requires an Apple iPhone<\/a>.<\/p>\n

How do you identify sleep issues while awake?<\/h2>\n

Optalert\u2019s breakthrough test relies on years of research in the sleep science space but is simple for anyone to do. You position yourself and the phone in a quiet, well-lit environment and count the number of diamonds that appear in a simple vigilance test. The resulting micro-movements of your eyelid \u2013 blinks, flutters, twitches \u2013 are captured using the smartphone\u2019s front-facing camera. A complex, proprietary algorithm then analyses your eyelid signal, deriving 64 distinct parameters and identifying any neurocognitive impairment that stems from a sleep issue. You then see the result immediately.<\/p>\n

The test is now available in Australia as an app for the Apple iPhone. The app also aims to improve your overall quality of sleep, offering links to a range of products that can help you get a better night\u2019s rest, as well as a range of evidence-based articles on sleep health<\/span>.<\/p>\n

Superior accuracy in less time<\/h2>\n\n\n\n
\n
\"\"<\/div>\n<\/td>\n
\n
\n

\u201cWearable and app-based technologies are transforming how we approach sleep, and brain health more generally. These technologies provide continuous, personalised data that helps in identifying sleep issues, and thereby promote treatments of underlying conditions that affect the brain.\u201d<\/em><\/p>\n<\/div>\n

\u2013 Prof. Matthew Kiernan AM,
\nCEO Neuroscience Research Australia<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

In terms of performance, the new technology is world-class. With an accuracy of 96.6%, Optalert\u2019s test sets a new standard for what can be captured without in-clinic polysomnography (PSG).<\/p>\n

Despite only taking minutes to complete, Optalert\u2019s solution achieves greater accuracy than similar consumer-facing tests in leading smartwatches. These tests primarily rely on interpreting a user\u2019s breathing across multiple nights using the watch\u2019s on-board accelerometer, with some also using pulse oximetry to capture blood oxygenation levels.<\/p>\n

However, only 17.3% of Australians own a compatible smartwatch, making them inaccessible for most. Optalert\u2019s solution is designed for the Apple iPhone \u2013 a device owned by more than 50% of Australians. The new test represents a step change in expanding access to sleep health technologies, while delivering greater accuracy in a shorter amount of time.<\/p>\n

A history of scientific breakthrough and research collaboration<\/h2>\n

\"\"The test leverages expertise gained in developing Optalert\u2019s first biomarker: the Johns Drowsiness Scale (JDS). The JDS is a method of quantifying impairment due to drowsiness and is used in sleep laboratories around the world. In addition, it also has wide commercial application, currently deployed in driver monitoring systems to help protect drivers in fleets against accidents and injuries resulting from driver fatigue.<\/p>\n

Data collection for Optalert\u2019s new model took place in three leading sleep laboratories: Monash Medical Centre<\/a>, the Monash Biomedicine Discovery Institute<\/a>, and the Institute for Breathing and Sleep (IBAS)<\/a>.<\/p>\n

Approximately one in five Australians are estimated to be affected by a major sleep disorder, which is estimated to cost AU$56.5 billion annually.[1]<\/a> Consequently, increased awareness of sleep health is vital to the health of Australians and our economy.<\/p>\n

Our current algorithm is part of a broader-reaching transformation making medical technologies available to consumers at low or no cost. We are also developing a biomarker that detects Alzheimer\u2019s disease and we have active research on patients with epilepsy and traumatic brain injury. We envision a future in which smart devices passively monitor us in the background, and alert us to subtle signs of increasing impairment. Early intervention for such conditions can add many years of healthful life to millions of people.<\/p>\n

[1]<\/a> Streatfeild J, Smith J, Mansfield D, Pezzullo L, Hillman D. The social and economic cost of sleep disorders. Sleep. 2021 Nov 12;44(11):zsab132. doi: 10.1093\/sleep\/zsab132. PMID: 34015136.<\/p>\n